Amneal Pharmaceuticals, Inc. AMRX R2KR3KPHARMA
Company Overview
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Why Investors Should Care
Revenue has grown at a 14.5% CAGR over the past five years.
Operating margin of 18.3% supports profitability.
Recent Developments
- Dec 2025 Revenue of $3.02B (+8.0% YoY); net profit $72.06M.
- Trailing 12 Months Year-on-year growth — revenue +9.9%, earnings +157.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.55% |
| 1 Year: | 9.90% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 157.10% |
Stock Price Performance
| 1 Year: | +117.87% |
| 6 Months: | +61.90% |
| 3 Months: | +14.29% |
| 1 Month: | +5.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.26 · Neutral
P/E of 41.80 is above the sector median of 25.61 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 14.5% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMRX Amneal Pharmaceuticals, Inc. R2KR3KPHARMA | 20.48 | 41.80 | $7.13B | 0.00% | 14.23% | - | 14.55% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 225.68M | 259.87M | 254.73M | 293.37M | 275.19M | 413.79M | 476.49M | 497.53M | 446.12M | 404.64M | 378.28M | 397.33M | 498.53M | 464.66M | 519.29M | 493.11M | 535.08M | 528.59M | 497.63M | 559.36M | 545.56M | 557.54M | 599.05M | 620.04M | 659.19M | 701.78M | - | - | 695.42M | 724.51M | 784.51M | 814.32M | 722.52M | 796.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 439.53M | 438.25M | 510.54M | 517.13M | 402.41M | - |
| Gross Profit | 116.02M | 123.73M | 135.01M | 151.42M | 144.59M | 178.29M | 200.10M | 193.41M | 83.08M | 105.25M | 54.43M | 110.23M | 183.50M | 144.24M | 133.59M | 191.56M | 212.50M | 198.51M | 174.57M | 200.52M | 194.23M | 178.19M | 220.02M | 232.53M | 238.06M | 249.95M | - | - | 255.89M | 286.25M | 273.97M | 297.19M | 320.11M | 334.51M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154.97M | 174.25M | 203.49M | 182.69M | 171.84M | - |
| Operating Income | - | 44.60M | 78.75M | - | 63.55M | -181.06M | 74.56M | - | -94.36M | -18.91M | -112.27M | - | 57.79M | 10.75M | 2.44M | 45.91M | 67.12M | 28.52M | 23.30M | -198.62M | 44.35M | 34.45M | 80.08M | 75.65M | -10.75M | 95.47M | - | - | 100.92M | 112.01M | 70.49M | 114.50M | 148.27M | 129.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154.58M | 176.93M | 111.66M | 160.70M | 176.73M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.94M | 65.10M | 62.81M | 56.24M | 53.36M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.49M | 51.71M | -5.22M | 55.23M | 80.18M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.87M | 16.10M | -23.36M | 5.66M | 2.18M | - |
| Net Income | - | 0 | 0 | 0 | 0 | -17.86M | 6.89M | - | -47.88M | -16.90M | -265.01M | - | 120.43M | -24.16M | -21.64M | 12.75M | 29.99M | -7.78M | -8.82M | -242.13M | -7.61M | -6.94M | 11.92M | 9.68M | -91.64M | 5.99M | - | - | 12.20M | 22.42M | 2.37M | 35.08M | 62.26M | 57.66M |
| Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.15 | 0.05 | -0.07 | -0.37 | -0.13 | -2.03 | -0.23 | 0.78 | -0.08 | -0.06 | 0.04 | 0.10 | -0.03 | -0.01 | -0.80 | -0.02 | -0.05 | 0.08 | 0.06 | -0.30 | 0.02 | - | - | 0.04 | 0.07 | 0.01 | 0.11 | 0.19 | 0.18 |
| R&D Expense | - | 47.18M | 41.32M | - | 44.21M | 50.34M | 42.35M | - | 53.86M | 48.02M | 38.12M | - | 36.38M | 45.57M | 44.52M | 48.18M | 52.86M | 48.93M | 52.80M | 50.75M | 50.23M | 38.69M | 37.80M | 41.38M | 39.30M | 36.05M | 61.10M | - | 40.04M | 47.96M | 63.35M | - | 38.38M | 39.02M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.02B | 1.03B | 1.66B | 1.63B | 1.99B | - | 2.21B | 2.39B | 2.79B | 3.02B |
| Cost of Revenue | - | - | - | - | - | - | 1.43B | 1.57B | 1.77B | 1.91B |
| Gross Profit | 597.46M | 526.18M | 716.40M | 353.00M | 628.39M | - | 784.71M | 820.57M | 1.02B | 1.11B |
| Operating Expenses | - | - | - | - | - | - | 595.79M | 581.82M | 672.07M | 715.39M |
| Operating Income | 284.88M | 245.10M | -19.67M | -248.68M | 91.16M | - | 188.92M | 238.75M | 348.37M | 397.91M |
| EBITDA | - | - | - | - | - | - | 150.43M | 399.76M | 439.77M | 603.87M |
| Interest Expense | - | - | - | - | - | - | 158.38M | 210.63M | 258.60M | 241.09M |
| Pretax Income | - | - | - | - | - | - | -248.13M | -40.27M | -55.01M | 139.21M |
| Tax Provision | - | - | - | - | - | - | 6.66M | 8.45M | 18.86M | 11.28M |
| Net Income | 0 | 0 | -19.74M | -603.57M | 67.79M | - | -129.99M | -83.99M | -116.89M | 72.06M |
| Diluted EPS | - | - | -0.16 | -2.74 | 0.61 | - | -0.86 | -0.48 | -0.38 | 0.22 |
| R&D Expense | 179.02M | 171.42M | 194.19M | 188.05M | 179.93M | 201.85M | 195.69M | 163.95M | 190.71M | 186.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Oct 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.34B | 4.35B | 3.67B | 4.01B | - | 3.80B | 3.47B | 3.50B | 3.68B |
| Current Assets | - | - | - | - | - | - | - | 1.41B | 1.38B | 1.59B | 1.91B |
| Cash & Equivalents | 27.37M | 0 | 74.17M | 213.39M | 151.20M | 341.38M | - | 25.98M | 91.54M | 110.55M | 282.03M |
| Inventory | - | - | - | - | - | - | - | 530.74M | 581.38M | 612.45M | 606.30M |
| Receivables | - | - | - | - | - | - | - | 741.79M | 613.73M | 775.73M | 895.14M |
| Total Liabilities | - | - | 0 | - | - | - | - | 3.62B | 3.45B | 3.61B | 3.75B |
| Current Liabilities | - | - | 296.88M | 553.85M | 550.41M | 676.90M | - | 752.80M | 846.60M | 1.13B | 881.63M |
| Long Term Debt | - | - | 1.36B | 2.63B | 2.61B | 2.74B | - | 2.63B | 2.43B | 2.16B | 2.57B |
| Total Debt | - | - | - | - | - | - | - | 2.85B | 2.75B | 2.59B | 2.69B |
| Total Equity | - | 0 | 0 | 504.75M | 232.01M | 303.27M | - | 298.42M | 19.78M | -109.27M | -70.79M |
| Shares Outstanding | - | - | - | - | - | - | - | 151.49M | 306.56M | 309.88M | 314.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 115.06M | 234.19M | 250.23M | 1.71M | 379.00M | - | 65.10M | 345.58M | 295.10M | 339.99M |
| Investing Cash Flow | -124.61M | -98.55M | -396.38M | -19.58M | -317.55M | - | -174.31M | -69.19M | -63.00M | -112.26M |
| Financing Cash Flow | -19.50M | -95.02M | 287.68M | -45.83M | 131.81M | - | -106.62M | -212.57M | -211.79M | -31.53M |
| Capital Expenditure | -122.76M | -94.77M | -83.09M | -47.18M | -56.45M | - | -90.59M | -69.19M | -74.99M | -114.36M |
| Free Cash Flow | -7.70M | 139.42M | 167.14M | -45.48M | 322.56M | - | -25.50M | 276.39M | 220.11M | 225.63M |
| Net Change in Cash | - | - | - | - | - | - | -215.83M | 63.81M | 20.31M | 196.20M |
| Dividends Paid | 200.62M | 375.26M | 183.00M | 0 | 0 | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 58.7% | 50.9% | 43.1% | 21.7% | 31.5% | - | 35.5% | 34.3% | 36.5% | 36.9% |
| Operating Margin % | 28.0% | 23.7% | -1.2% | -15.3% | 4.6% | - | 8.5% | 10.0% | 12.5% | 13.2% |
| Net Margin % | 0.0% | 0.0% | -1.2% | -37.1% | 3.4% | - | -5.9% | -3.5% | -4.2% | 2.4% |
| ROE % | - | - | -3.9% | -260.1% | 22.4% | - | -43.6% | -424.6% | 107.0% | -101.8% |
| ROCE % | - | 23.5% | -0.5% | -8.0% | 2.7% | - | 6.2% | 9.1% | 14.7% | 14.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.67% | 26.56M | $528.85M |
| 2 | TPG GP A, LLC | 4.02% | 12.33M | $245.47M |
| 3 | Vanguard Portfolio Management LLC | 3.96% | 12.14M | $241.66M |
| 4 | Rubric Capital Management LP | 3.32% | 10.17M | $202.46M |
| 5 | Vanguard Capital Management LLC | 2.52% | 7.71M | $153.51M |
| 6 | State Street Corporation | 2.40% | 7.36M | $146.48M |
| 7 | Dimensional Fund Advisors LP | 1.89% | 5.79M | $115.36M |
| 8 | Geode Capital Management, LLC | 1.68% | 5.14M | $102.33M |
| 9 | Morgan Stanley | 1.34% | 4.11M | $81.83M |
| 10 | Neuberger Berman Group, LLC | 1.27% | 3.89M | $77.39M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AMRX
1 Russell 2000 Stock with Competitive Advantages and 2 Facing Challenges
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size …
1 Profitable Stock for Long-Term Investors and 2 Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
3 Overrated Stocks We Think Twice About
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.…
Amneal to Report Third Quarter 2026 Results on November 3, 2026
BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market op…
3 Low-Volatility Stocks with Open Questions
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Amneal Pharmaceuticals (AMRX) Stock Gets Fair Value Bump After Analyst Backing For New Launches
The analyst fair value estimate for Amneal Pharmaceuticals has shifted from US$22.00 to about US$22.71 per share, reflecting updated price targets within the US$20 to US$27 range that are guiding much of the current discussion. Analysts are…
AMRX — Frequently Asked Questions
What is the current share price of Amneal Pharmaceuticals, Inc. (AMRX)?
As of 2026-10-22 16:30 PDT, Amneal Pharmaceuticals, Inc. (AMRX) trades at $20.48 on NasdaqGS. Its 52-week range is $9.26 to $20.50.
What is the market capitalisation of AMRX?
Amneal Pharmaceuticals, Inc. (AMRX) has a market capitalisation of $7.13B on NasdaqGS.
What is the P/E ratio of AMRX?
AMRX trades at a trailing price-to-earnings (P/E) ratio of 41.80. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 193.30.
Is AMRX a good stock to buy?
This page provides a data-driven analysis of Amneal Pharmaceuticals, Inc. (AMRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.